Th17 cells show a great degree of change and convert to Th1 cells. Anticancer immunity is provided by IFN-\(\gamma\)-producing T helper cells [13]. Over the last decade, ex vivo generated DCs and in vitro targeting DCs have been extensively studied as potential cancer vaccines [11]. Meanwhile, several DC-based cancer vaccine trials against specific antigens have been conducted, such as ovarian cancer, prostate cancer, metastatic melanoma cancer, glioblastoma, and pancreatic cancer [14]. However, it has been reported that DC-based cancer vaccines are not so effective in clinical trials due to low maturation, migration, and reduced IL-12 secretion [15; 16]. For this reason, the ex vivo-generated DCs need to be stimulated by adjuvant to make fully matured DCs with increased IL-12 secretion from these cells [17]. Recently, the Food and Drug Administration of the USA approved a DC-based vaccine against human prostate cancer named Sipuleucel-T. It has been shown that early-stage of clinical trials of DC-based cancer vaccines increase the nonspecific immune responses in cancer patients with aggressive tumor progression and immune dysfunction that limit the effectiveness of the vaccines [11; 18]. To overcome this problem, tumor cell lysate (TCL)-loaded DCs with phytomolec adjuvant increased the effectiveness of vaccines in an in vivo animal model [18]. The medicine from plant extracts and its active components has immunomodulatory effects on the maturation of DCs [19; 20]. Plant-derived polysaccharides (PDPs) can stimulate the maturation of DCs and present internalized antigens to naive T-cells. The naive T-cells activate T-cells and remove the tumor. The plant-derived polysaccharides (PDPs) can also be used as adjuvarts in DC-based cancer vaccines or act as independent agents in intrinsic anti-tumor activities [21]. Mixed polysaccharide fractions from plant roots enhance the efficiency of the DC-based cancer vaccine against metastasis of 4T1 mammary carcinoma in mice [18]. Traditional herbal medicine can reduce the toxicity of chemotherapy and radiotherapy and enhance anti-tumor therapies with decreased cancer-derivedpains#. It also reduces postoperative complications and increases the survivability of cancer patients [22]. Another report showed that immunomodulatory activity on the human Monocyte-Derived Dendritic Cell (MDDCs) vaccine, which was pulsed with plant extract and human papillomavirus 16 (HPV16) tumor protein and was shown to be effective against HPV16 related tumors in an animal model [23]. Plant extract of Oregon grape (_Mahonia aquifolium_) stimulates peripheral blood mononuclear cells (PBMCs) and induces cytotoxicity and apoptosis of the tumor cells [24]. [PERSON] et al. investigated Mauritius endemic plants (_Psiadia lithospermifolia_, plants from the Asteraceae family) for anticancer activities in T-cell lymphoma and melanoma cells. They also found that plant extract components have potential anticancer activities in vitro studies [25]. Plant tuber extract (_Dioscorea alata_ var. _purpurea_) acts as an adjuvant of bone-marrow-derived dendritic cell (DC) based vaccine for cancer immunotherapy [26]. The maturation of dendritic cells is important for initiating immune responses. The tumor microenvironment inhibits the maturation of DCs, and it is a great problem for DC-based tumor immunotherapy. PDPs induce phenotypic and functional maturation of DCs [27]. Alcoholic extracts of plants (_Tinospora cordifolia_) induce the differentiation of dendritic cells from macrophages in the presence of granulocyte-macrophage colony-stimulating factor (GMCSF), TNF, and IL-4 [28]. It has been proven that most therapeutic plants can modulate DC activities and can be used as a therapeutic target to treat cancer [29]. For this reason, this review discusses the potential application of phytochemicals in dendritic cell (DC)-based cancer immunotherapy.